Cargando…

Progression of glucose‐lowering diabetes therapy in TECOS

AIMS: TECOS was a randomized, double‐blind, placebo‐controlled trial assessing the impact of sitagliptin vs. placebo on cardiovascular outcomes when added to usual care in patients with type 2 diabetes. We report the use of concomitant diabetes medications and the risk for progression to insulin dur...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bethel, M. Angelyn, Engel, Samuel S., Stevens, Susanna R., Lokhnygina, Yuliya, Ding, Jie, Josse, Robert G., Alvarsson, Michael, Hramiak, Irene, Green, Jennifer B., Peterson, Eric D., Holman, Rury R.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2018
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6354756/ https://www.ncbi.nlm.nih.gov/pubmed/30815579 http://dx.doi.org/10.1002/edm2.53

Ejemplares similares

Pancreatic Safety of Sitagliptin in the TECOS Study
por: Buse, John B., et al.
Publicado: (2017)

Sitagliptin does not reduce the risk of cardiovascular death or hospitalization for heart failure following myocardial infarction in patients with diabetes: observations from TECOS
por: Nauck, Michael A., et al.
Publicado: (2019)

Time-dependent event accumulation in a cardiovascular outcome trial of patients with type 2 diabetes and established atherosclerotic cardiovascular disease
por: Bethel, M. Angelyn, et al.
Publicado: (2023)

Development and validation of a model to predict cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke in patients with type 2 diabetes mellitus and established atherosclerotic cardiovascular disease
por: Stevens, Susanna R., et al.
Publicado: (2022)

Effect of race on cardiometabolic responses to once-weekly exenatide: insights from the Exenatide Study of Cardiovascular Event Lowering (EXSCEL)
por: Davis, Timothy M. E., et al.
Publicado: (2022)

Evaluation of a Self-Administered Oral Glucose Tolerance Test
por: Bethel, M. Angelyn, et al.
Publicado: (2013)

Plasma levels of DPP4 activity and sDPP4 are dissociated from inflammation in mice and humans
por: Baggio, Laurie L., et al.
Publicado: (2020)

Gliptins and Cardiovascular Outcomes: A Comparative and Critical Analysis after TECOS
por: Ghosal, Samit, et al.
Publicado: (2016)

Meta-analysis of the impact of alpha-glucosidase inhibitors on incident diabetes and cardiovascular outcomes
por: Coleman, Ruth L., et al.
Publicado: (2019)

Relationship between baseline physical activity assessed by pedometer count and new-onset diabetes in the NAVIGATOR trial
por: Kraus, William E, et al.
Publicado: (2018)

Prediction and validation of exenatide risk marker effects on progression of renal disease: Insights from EXSCEL
por: Idzerda, Nienke M. A., et al.
Publicado: (2020)

Effect of Once‐Weekly Exenatide on Clinical Outcomes According to Baseline Risk in Patients With Type 2 Diabetes Mellitus: Insights From the EXSCEL Trial
por: Mentz, Robert J., et al.
Publicado: (2018)

Validation of the WATCH‐DM and TRS‐HF(DM) Risk Scores to Predict the Risk of Incident Hospitalization for Heart Failure Among Adults With Type 2 Diabetes: A Multicohort Analysis
por: Segar, Matthew W., et al.
Publicado: (2022)

Role of diuretics, β blockers, and statins in increasing the risk of diabetes in patients with impaired glucose tolerance: reanalysis of data from the NAVIGATOR study
por: Shen, Lan, et al.
Publicado: (2013)

Re‐adjudication of the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS) with study‐level meta‐analysis of hospitalization for heart failure from cardiovascular outcomes trials with dipeptidyl peptidase‐4 (DPP‐4) inhibitors
por: Scirica, Benjamin M., et al.
Publicado: (2022)

Glucose-Lowering Medications and Post-Dementia Survival in Patients with Diabetes and Dementia
por: Secnik, Juraj, et al.
Publicado: (2022)

Health utilities in Chinese patients with coronary heart disease and impaired glucose tolerance (ACE): A longitudinal analysis of a randomized, double‐blind, placebo‐controlled trial
por: Leal, José, et al.
Publicado: (2022)

Comparison of different methods used in drugs of abuse for sample validity testing including pH methods, specific gravity methods, TECO™ Drug Adulteration Test Strip and oxidant assay
por: Mina, Ashraf, et al.
Publicado: (2021)

Comparison of regression imputation methods of baseline covariates that predict survival outcomes
por: Solomon, Nicole, et al.
Publicado: (2020)

A retrospective analysis of amputation rates in diabetic patients: can lower extremity amputations be further prevented?
por: Alvarsson, Alexandra, et al.
Publicado: (2012)

Lixisenatide in type 1 diabetes: A randomised control trial of the effect of lixisenatide on post‐meal glucose excursions and glucagon in type 1 diabetes patients
por: Ballav, Chitrabhanu, et al.
Publicado: (2020)

2159. Methodological Threats to the Standardized Infection and Standardized Antimicrobial Administration Ratios
por: Lofgren, Eric, et al.
Publicado: (2018)

Impact of differing glucose‐lowering regimens on the pattern of association between glucose control and survival
por: Currie, Craig J., et al.
Publicado: (2017)

Effect of expanded dulaglutide weekly doses (3.0 mg and 4.5 mg) on cardiovascular disease risk factors in participants with type 2 diabetes at increased cardiovascular disease risk: a post hoc analysis of the AWARD‐11 study
por: Cox, David A., et al.
Publicado: (2022)

Second-Generation Insulin Analogues – a Review of Recent Real-World Data and Forthcoming Head-to-Head Comparisons
por: Mauricio, Didac, et al.
Publicado: (2018)

International Variation in Outcomes Among People with Cardiovascular Disease or Cardiovascular Risk Factors and Impaired Glucose Tolerance: Insights from the NAVIGATOR Trial
por: Harumi Higuchi dos Santos, Marilia, et al.
Publicado: (2017)

The impact of individualised cardiovascular disease (CVD) risk estimates and lifestyle advice on physical activity in individuals at high risk of CVD: a pilot 2 × 2 factorial understanding risk trial
por: Price, Hermione C, et al.
Publicado: (2008)

Economic Evaluation of Factorial Trials: Cost-Utility Analysis of the Atorvastatin in Factorial With Omega EE90 Risk Reduction in Diabetes 2 × 2 × 2 Factorial Trial of Atorvastatin, Omega-3 Fish Oil, and Action Planning
por: Dakin, Helen A., et al.
Publicado: (2020)

Initiating Insulin as Part of the Treating To Target in Type 2 Diabetes (4-T) Trial: An interview study of patients' and health professionals' experiences
por: Jenkins, Nicholas, et al.
Publicado: (2010)

Historical HbA(1c) Values May Explain the Type 2 Diabetes Legacy Effect: UKPDS 88
por: Lind, Marcus, et al.
Publicado: (2021)

HbA(1c) Change and Diabetic Retinopathy During GLP-1 Receptor Agonist Cardiovascular Outcome Trials: A Meta-analysis and Meta-regression
por: Bethel, M. Angelyn, et al.
Publicado: (2021)

Efficacy of Dulaglutide Expanded Doses by Baseline A1C Categories: Post Hoc Analysis of AWARD-11
por: Frias, Juan Pablo, et al.
Publicado: (2021)

1823. Signal or Noise? A Comparison of Methods to Identify Outliers in Antimicrobial Use (AU)
por: Moehring, Rebekah W, et al.
Publicado: (2018)

Temporal Validation of the UKPDS Outcomes Model Using 10-Year Posttrial Monitoring Data
por: Leal, Jose, et al.
Publicado: (2013)

Health selection into neighborhoods among patients enrolled in a clinical trial
por: Arcaya, Mariana C., et al.
Publicado: (2017)

Accurately Reflecting Uncertainty When Using Patient-Level Simulation Models to Extrapolate Clinical Trial Data
por: Dakin, Helen A., et al.
Publicado: (2020)

Predictors of cardiovascular events in a contemporary population with impaired glucose tolerance: an observational analysis of the Nateglinide and Valsartan in impaired glucose tolerance outcomes research (NAVIGATOR) trial
por: Preiss, David, et al.
Publicado: (2012)

MON-370 Isolated Secondary Adrenal Insufficiency in the Absence of Hypophysitis Secondary to Immune Checkpoint Inhibitors
por: Lu, Mary, et al.
Publicado: (2019)

Challenges of maintaining research protocol fidelity in a clinical care setting: A qualitative study of the experiences and views of patients and staff participating in a randomized controlled trial
por: Lawton, Julia, et al.
Publicado: (2011)

Role of Glucose-Lowering Medications in Erectile Dysfunction
por: Cignarelli, Angelo, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_jema78ea0664f05sdb2q4psakp